Presentation is loading. Please wait.

Presentation is loading. Please wait.

Transient HAART During PHI Prolongs the Total Time Off HAART in Patients Presenting with PHI: Data from the Dutch Primo-SHM Cohort R. Steingrover, S. Jurriaans,

Similar presentations


Presentation on theme: "Transient HAART During PHI Prolongs the Total Time Off HAART in Patients Presenting with PHI: Data from the Dutch Primo-SHM Cohort R. Steingrover, S. Jurriaans,"— Presentation transcript:

1 Transient HAART During PHI Prolongs the Total Time Off HAART in Patients Presenting with PHI: Data from the Dutch Primo-SHM Cohort R. Steingrover, S. Jurriaans, J. Lange, J.M. Prins on behalf of the Primo-SHM study group

2 Introduction Is temporary HAART during PHI beneficial? To the individual: –lower plasma viral load set-point? –longer time off HAART?

3 Yes: –Girard, AIDS 2001 –Hecht, JID 2006 –Fidler, AIDS 2007 –Steingrover, CROI 2007 No: –Markowitz, JID 2002 –Fidler, AIDS 2002 –Desquilbet, AIDS 2004 –Streeck, JID 2006 Lower viral set-point in cohort studies?

4 Lower viral set-point: RCT Steingrover et al, Temporary ART During PHI Lowers the Viral Set-point: the Prospective Randomized Trial Primo-SHM CROI 2008, poster 698b

5 Introduction Is temporary HAART during PHI beneficial? To the individual: –lower plasma HIV viral load? –longer time off HAART?

6 Introduction Is temporary HAART during PHI beneficial? To the individual: –lower plasma HIV viral load? –longer time off HAART? Objective of current analysis

7 Methods Patients with PHI –Negative/indeterminate WB –Detectable plasma HIV-1 RNA –or –Negative screening < 180 days Participating in Prospective Primo-SHM Trial or Cohort

8 Methods Primo-SHM Trial: randomization –No treatment –24 weeks early HAART –60 weeks early HAART Primo-SHM Cohort: physician/patient choice: –No treatment –early HAART

9 Methods Objectives, to analyze: –the effect of transient HAART during PHI: the total time off antiretroviral therapy –factors associated with a longer total time off HAART

10 Methods Endpoint: restart of HAART Two times CD4 < 350 Symptomatic HIV-1 disease CDC-B or C Statistical analysis: Corrected KM Corrected Cox proportional hazards analysis

11 Correction of KM analysis

12

13

14 Results 141 Patients identified at Feb 1 st in the analysis

15 Flow of patients

16 Baseline and epidemiological data Untreatedearly HAARTP N4755 Age38 (36-41)40 ( Male45 (96%)53 (96%)0.7 MSM37 (79%)46 (84%)0.5 Caucasian37 (79%)52 (95%)0.2 HIV-1 RNA5.2 ( )4.9 ( )0.1 CD4 cells516 ( )565 ( )0.3 Wks SC to HAART-5 (3-7) Duration of early HAART (wks, range) -28 (21-62)

17 Results (contd) 47 untreated –23 started HAART for low CD4 count, 2 for symptomatic HIV-1 disease 55 early HAART + interruption –10 restarted HAART, all for low CD4 counts UntreatedTransient HAARTp CD4 at (re)start 222 ( )254 ( )0.4

18

19 Kaplan Meier plot of the time to (re)start HAART, corrected for the duration of early HAART p = 0.001

20 Results corrected KM Total time off HAART: –126 (95%CI: ) weeks for untreated patients –181 ( ) weeks for treated patients –p=0.001

21

22 The time to (re)start HAART in the Cox' proportional hazards model adjusted for age and baseline CD4 count. p < 0.001

23 Conclusion Transient, early HAART during PHI prolongs the total time that patients can remain off HAART Other independent predictors: –Age –CD4 count at baseline Note: pVL at baseline is not an independent predictor

24 Discussion What is the effect of details of early treatment: –timing –duration Is treatment of PHI worth the effort? Confirmed by randomized trials? –Primo-SHM –SPARTAC

25 Acknowledgements AMC Dpt Internal Medicine - Jan Prins -Marlous Grijsen -Joep Lange -Nicollette Hulshof, Marian Nievaard, Bonnie Slegtenhorst Harold Doevelaar Dpt Experimental Immunology - Hanneke Schuitemaker Dpt Medical Microbiology -Suzanne Jurriaans, Nicole Back -Dpt Experimental Virology -Georgios Pollakis UMC Utrecht Dpt Immunology - Frank Miedema HIV monitoring foundation -Frank de Wolf - Rosalind Beard Participating sites Maastricht UMC EMC, Rotterdam HAGA, Den Haag KGH, Haarlem Leiden UMC MC Leeuwarden MST, Enschede OLVG, Amsterdam St. Elizabeth, Tilburg UMC Nijmegen All study participants


Download ppt "Transient HAART During PHI Prolongs the Total Time Off HAART in Patients Presenting with PHI: Data from the Dutch Primo-SHM Cohort R. Steingrover, S. Jurriaans,"

Similar presentations


Ads by Google